Submitted:
09 November 2026
Posted:
10 November 2026
You are already at the latest version
Abstract
Background and Objectives: Secondary hypogammaglobulinemia (SHG) is common in hematologic malignancy, transplantation, and B-cell- or plasma-cell-directed therapy. Because secondary antibody deficiency (SAD) can occur despite near-normal total IgG, thresholds for investigation and immunoglobulin replacement therapy (IgRT) remain inconsistent.
Materials and Methods: The 2023 Lithuanian consensus was developed by seven allergologists and clinical immunologists from two tertiary academic centers. Six authors updated it through targeted PubMed/MEDLINE searches and review of professional-society, regulatory, and national guidance in August 2026. Evidence selection prioritized guidelines, reviews, comparative studies, and real-world data. This was a structured narrative review and expert consensus without GRADE assessment or Delphi voting.
Results: Twenty-nine recommendations address assessment, infection, IgRT initiation and dosing, route, safety, monitoring, home treatment, and withdrawal. Decisions integrate infection burden, IgG concentration, specific-antibody function, comorbidity, lung disease, ongoing immunosuppression, and expected immune recovery. A usual starting dose is 0.4–0.6 g/kg/month, individualized to clinical response. Active infection is not an absolute contraindication to IgRT. Conclusions: These recommendations provide a practical Lithuanian approach to SAD and SHG and support individualized use of intravenous, conventional subcutaneous, and facilitated subcutaneous IgRT rather than treatment based solely on an IgG threshold.
Keywords:
secondary antibody deficiency
; secondary hypogammaglobulinemia
; immunoglobulin replacement therapy
; intravenous immunoglobulin
; subcutaneous immunoglobulin
; B-cell-targeted therapy
; consensus recommendations
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.